Pharmacological Effect of Nitroprusside on Platelet Aggregation

Journal of Extra-Corporeal Technology

Volumn 31, Issue 4, 1999, Pages 162-168

  Parrish, Pamela R ^a   Larson, Douglas F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

ADP; Aggregation assay; Cardiopulmonary bypass; Nitric oxide; PAF

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; THROMBOCYTE ACTIVATING FACTOR;

ADULT; BLOOD PRESSURE REGULATION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG INHIBITION; HUMAN; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 0033504244     PISSN: None     EISSN: 29698960     Source Type: Journal    
DOI: 10.1051/ject/1999314162     Document Type: Conference Paper

References (31)

1. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg. 1998;66:2135–44.
2. Murkin JM. Cardiopulmonary bypass and the inflammatory response: A role for serine protease inhibitors? J Cardiothorac Vasc Anesth. 1997;11:19–23.
3. Li J, Sly MK, Chao R et al. Transient adhesion of platelets in pump-oxygenator systems: Influence of SMA and nitric oxide treatments. J Biomater Sci Polym Ed. 1999;10:235–46.
4. Hyde JA, Chinn JA, Graham TR. Platelets and cardiopulmonary bypass. Perfusion. 1998;13:389–407.
5. Holada K, Simak J, Kucera V, et al. Platelet membrane receptors during short cardiopulmonary bypass—A flow cytometric study. Perfusion. 1996;11:401–6.
6. Kornecki E, Lenox RH, Hardwick DH, et al. Interactions of the alkyl-ether-phospholipid, platelet activating factor (PAF) with platelets, neural cells, and the psychotropic drugs triazolobenzodiazepines. Adv Exp Med Biol. 1987; 221:477–88.
7. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol. 1994;72:278–84.
8. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int Suppl. 1996;55:S2–S5.
9. Pallas F, Larson DF. Cerebral blood flow in the diabetic patient. Perfusion. 1996;11:363–70.
10. Luscher TF. Platelet–vessel wall interaction: Role of nitric oxide, prostaglandins, and endothelins. Baillieres Clin Haematol. 1993;6:609–27.
11. Radomski MW, Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol. 1993;344:251–64.
12. Stewart AG, Phan LH, Grigoriadis G. Physiological and pathophysiological roles of nitric oxide. Microsurgery. 1994;15:693–702.
13. Massoudy P, Zahler S, Barankay A, et al. Sodium nitroprusside during coronary artery bypass grafting: Evidence for an anti-inflammatory action. Ann Thorac Surg. 1999; 67:1059–64.
14. Morgan GE, Mikhail MS. Hypotensive agents. Clin Anesthesiol. 1996;186–92.
15. Gold ME. Pharmacology of the nitrovasodilators. Antianginal, antihypertensive, and antiplatelet actions. Nurs Clin North Am. 1991;26:437–50.
16. Rao GH, Rao AT. Pharmacology of platelet activation-inhibitory drugs. Indian J Physiol Pharmacol. 1994;38:69–84.
17. Gachet C, Cazenave JP. ADP-induced blood platelet activation: A review. Nouv Rev Fr Hematol. 1991;33:347–58.
18. Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass (see comments). Blood. 1993;82:107–17.
19. Mustard JF, Kinlough-Rathbone RL, Packham MA. Platelet activation—An overview. Agents Actions Suppl. 1987; 21:23–36.
20. Weksler BB. Platelets and the inflammatory response. Clin Lab Med. 1983;3:667–76.
21. Irani MS, Izzat NN, Jones JW. Platelet function, coagulation tests, and cardiopulmonary bypass: Lack of correlation between pre-operative and intra-operative whole blood lumi-aggregometry and peri-operative blood loss in patients receiving autologous platelet-rich plasma. Blood Coagul Fibrinolysis. 1995;6:428–32.
22. Ereth MH, Nuttall GA, Klindworth JT, et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg. 1997;85:259–64.
23. Kawahito K, Kobayashi E, Iwasa H, et al. Platelet aggregation during cardiopulmonary bypass evaluated by a laser light-scattering method. Ann Thorac Surg. 1999;67:79–84.
24. Menys VC, Belcher PR, Noble MI, et al. Impaired platelet aggregation after cardiopulmonary bypass in man: Enhancement of collagen-induced aggregation in whole blood and plasma by adrenaline ex vivo. Clin Sci (Colch). 1995;88:269–75.
25. Jung G, Razafindranaibe F, Elkouby A, et al. Modifications of platelet shape change and ATP release during cardiopulmonary bypass. Haemostasis. 1995;25:149–57.
26. Kawahito K, Mohara J, Misawa Y, et al. Platelet damage caused by the centrifugal pump: In vitro evaluation by measuring the release of alpha-granule packing proteins. Artif Organs. 1997;21:1105–9.
27. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998;66:2145–52.
28. Hatori N, Yoshizu H, Haga Y, et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs. 1994;18:904–10.
29. Friedman M, Sellke FW, Wang SY, et al. Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation. 1994;90:II262&7–II268.
30. Ferroni P, Speziale G, Ruvolo G, et al. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass—A possible correlation? Thromb Haemost. 1998;80:58–64.
31. Sly MK, Prager MD, Eberhart RC, et al. Inhibition of surface-induced platelet activation by nitric oxide. ASAIO J. 1995;41:M394–M398.